Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the voting results of its annual and special meeting of shareholders held on Sept. 22, 2026. According to the company, 46,452,598 common shares were represented at the meeting, amounting to 63.58% of outstanding shares as of the record date. The meeting results, including the approval of a legal name change and the election of directors, mark a significant step in the company’s evolution from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
Shareholders appointed Zeifmans LLP as auditor, approved setting the board at eight directors, and elected Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So as directors. Additionally, shareholders approved changing the company’s legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1. This follows the adoption of the Helus Pharma business name on Jan. 5 and reflects the company’s anticipated transformation.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs). These synthetic molecules are designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. It is also developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland.
The name change and board election are critical as Helus Pharma positions itself for commercialization. The company’s progress with HLP003 and HLP004 could offer new treatment options for mental health conditions, a sector with significant unmet need. For more information, visit www.helus.com.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
